Download MendeleyIdentification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.
Zak, M., Liederer, B.M., Sampath, D., Yuen, P.W., Bair, K.W., Baumeister, T., Buckmelter, A.J., Clodfelter, K.H., Cheng, E., Crocker, L., Fu, B., Han, B., Li, G., Ho, Y.C., Lin, J., Liu, X., Ly, J., O'Brien, T., Reynolds, D.J., Skelton, N., Smith, C.C., Tay, S., Wang, W., Wang, Z., Xiao, Y., Zhang, L., Zhao, G., Zheng, X., Dragovich, P.S.(2015) Bioorg Med Chem Lett 25: 529-541
- PubMed: 25556090
- DOI: https://doi.org/10.1016/j.bmcl.2014.12.026
- Primary Citation of Related Structures:
4WQ6 - PubMed Abstract:
Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likely source of the TDI signal, and replacement with other bicyclic systems was found to reduce or eliminate the TDI finding. A strategy of reducing the number of aromatic rings and/or lowering cLogD7.4 was then employed to significantly improve aqueous solubility. These efforts culminated in the discovery of 42, a compound with no evidence of TDI, improved aqueous solubility, and robust efficacy in tumor xenograft studies.
Organizational Affiliation:
Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address: mzak@gene.com.
